1. Home
  2. HAE vs BTG Comparison

HAE vs BTG Comparison

Compare HAE & BTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HAE
  • BTG
  • Stock Information
  • Founded
  • HAE 1971
  • BTG 2006
  • Country
  • HAE United States
  • BTG Canada
  • Employees
  • HAE N/A
  • BTG N/A
  • Industry
  • HAE Medical/Dental Instruments
  • BTG Precious Metals
  • Sector
  • HAE Health Care
  • BTG Basic Materials
  • Exchange
  • HAE Nasdaq
  • BTG Nasdaq
  • Market Cap
  • HAE 3.6B
  • BTG 4.2B
  • IPO Year
  • HAE 1991
  • BTG N/A
  • Fundamental
  • Price
  • HAE $62.98
  • BTG $2.82
  • Analyst Decision
  • HAE Strong Buy
  • BTG Buy
  • Analyst Count
  • HAE 9
  • BTG 3
  • Target Price
  • HAE $103.56
  • BTG $4.02
  • AVG Volume (30 Days)
  • HAE 1.4M
  • BTG 32.5M
  • Earning Date
  • HAE 02-06-2025
  • BTG 02-19-2025
  • Dividend Yield
  • HAE N/A
  • BTG 5.69%
  • EPS Growth
  • HAE 3.20
  • BTG N/A
  • EPS
  • HAE 2.54
  • BTG N/A
  • Revenue
  • HAE $1,373,515,000.00
  • BTG $1,902,030,000.00
  • Revenue This Year
  • HAE $7.56
  • BTG N/A
  • Revenue Next Year
  • HAE $3.13
  • BTG $43.26
  • P/E Ratio
  • HAE $24.76
  • BTG N/A
  • Revenue Growth
  • HAE 8.14
  • BTG N/A
  • 52 Week Low
  • HAE $58.80
  • BTG $2.20
  • 52 Week High
  • HAE $97.97
  • BTG $3.50
  • Technical
  • Relative Strength Index (RSI)
  • HAE 38.28
  • BTG 68.20
  • Support Level
  • HAE $58.80
  • BTG $2.58
  • Resistance Level
  • HAE $65.15
  • BTG $2.62
  • Average True Range (ATR)
  • HAE 2.76
  • BTG 0.10
  • MACD
  • HAE 0.34
  • BTG 0.04
  • Stochastic Oscillator
  • HAE 32.85
  • BTG 78.57

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

About BTG B2Gold Corp Common shares (Canada)

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other significant assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into a global market. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.

Share on Social Networks: